BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 7192191)

  • 1. Nomenclature of GM2-gangliosidoses.
    Nørby S
    Clin Genet; 1980 May; 17(5):320-2. PubMed ID: 7192191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Late-onset hexosaminidase A and hexosaminidase A and B deficiency: family study and review.
    Adams C; Green S
    Dev Med Child Neurol; 1986 Apr; 28(2):236-43. PubMed ID: 2940136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Molecular pathogenesis and therapeutic approach of GM2 gangliosidosis].
    Tsuji D
    Yakugaku Zasshi; 2013; 133(2):269-74. PubMed ID: 23370522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GM2 gangliosidoses in Spain: analysis of the HEXA and HEXB genes in 34 Tay-Sachs and 14 Sandhoff patients.
    Gort L; de Olano N; Macías-Vidal J; Coll MA;
    Gene; 2012 Sep; 506(1):25-30. PubMed ID: 22789865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Segregation of Tay-Sachs and Sandhoff alleles in a non-Jewish family.
    Lane AB; Young E; Jenkins T
    Am J Hum Genet; 1980 Nov; 32(6):920-6. PubMed ID: 7446530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apoptotic cell death in mouse models of GM2 gangliosidosis and observations on human Tay-Sachs and Sandhoff diseases.
    Huang JQ; Trasler JM; Igdoura S; Michaud J; Hanal N; Gravel RA
    Hum Mol Genet; 1997 Oct; 6(11):1879-85. PubMed ID: 9302266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Basic findings and current developments in sphingolipidoses.
    Pilz H; Heipertz R; Seidel D
    Hum Genet; 1979 Mar; 47(2):113-34. PubMed ID: 108196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The biochemical basis of gangliosidoses.
    Sandhoff K; Conzelmann E
    Neuropediatrics; 1984 Sep; 15 Suppl():85-92. PubMed ID: 6242704
    [No Abstract]   [Full Text] [Related]  

  • 9. Glycosphingolipid degradation and animal models of GM2-gangliosidoses.
    Kolter T; Sandhoff K
    J Inherit Metab Dis; 1998 Aug; 21(5):548-63. PubMed ID: 9728335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The GM2 gangliosidoses databases: allelic variation at the HEXA, HEXB, and GM2A gene loci.
    Cordeiro P; Hechtman P; Kaplan F
    Genet Med; 2000; 2(6):319-27. PubMed ID: 11339652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel gene editing system to treat both Tay-Sachs and Sandhoff diseases.
    Ou L; Przybilla MJ; Tăbăran AF; Overn P; O'Sullivan MG; Jiang X; Sidhu R; Kell PJ; Ory DS; Whitley CB
    Gene Ther; 2020 May; 27(5):226-236. PubMed ID: 31896760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Recent advances in molecular genetics of GM2 gangliosidosis].
    Wakamatsu N
    Nihon Rinsho; 1995 Dec; 53(12):2988-93. PubMed ID: 8577047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic heterogeneity of the hexosaminidase deficiency diseases.
    Johnson WG
    Res Publ Assoc Res Nerv Ment Dis; 1983; 60():215-37. PubMed ID: 6337393
    [No Abstract]   [Full Text] [Related]  

  • 14. [Study of the genetic heterogeneity of gangliosidoses in humans].
    Akhunov VS; Aronovich EL; Krasnopol'skaia KD; Mirenburg TV
    Genetika; 1989 Oct; 25(10):1861-71. PubMed ID: 2533574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient and caregiver perspectives on burden of disease manifestations in late-onset Tay-Sachs and Sandhoff diseases.
    Lyn N; Pulikottil-Jacob R; Rochmann C; Krupnick R; Gwaltney C; Stephens N; Kissell J; Cox GF; Fischer T; Hamed A
    Orphanet J Rare Dis; 2020 Apr; 15(1):92. PubMed ID: 32295606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suggestions for a nomenclature for the GM2 gangliosidoses making certain (possibly unwarrantable) assumptions.
    O'Brien JS
    Am J Hum Genet; 1978 Nov; 30(6):672-5. PubMed ID: 747190
    [No Abstract]   [Full Text] [Related]  

  • 17. Biochemical consequences of mutations causing the GM2 gangliosidoses.
    Mahuran DJ
    Biochim Biophys Acta; 1999 Oct; 1455(2-3):105-38. PubMed ID: 10571007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mouse models of Tay-Sachs and Sandhoff diseases differ in neurologic phenotype and ganglioside metabolism.
    Sango K; Yamanaka S; Hoffmann A; Okuda Y; Grinberg A; Westphal H; McDonald MP; Crawley JN; Sandhoff K; Suzuki K; Proia RL
    Nat Genet; 1995 Oct; 11(2):170-6. PubMed ID: 7550345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Genetic deficiencies of beta-N-acetylhexosaminidase A and B: Tay-Sachs and Sandhoff diseases (GM2-gangliosidosis)].
    Suzuki K
    Tanpakushitsu Kakusan Koso; 1988 Apr; 33(5):721-7. PubMed ID: 2978703
    [No Abstract]   [Full Text] [Related]  

  • 20. Detection of GM2-gangliosidosis (Tay-Sachs and Sandhoff disease) gene carriers by serum hexosaminidase assay.
    Molzer B; Bernheimer H
    Clin Chim Acta; 1976 Nov; 73(1):163-9. PubMed ID: 826357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.